Alnylam EVP of R&D looks forward to RNAi revolution as first approval appears imminent

10 November 2017

Boosted by his firm’s positive Phase III presentation at last week’s ATTR meeting, Alnylam Pharmaceuticals’ (Nasdaq: ALNY) EVP of research and development Akshay Vaishnaw won’t commit to saying that regulatory approval is inevitable, but he and president Barry Greene certainly give that impression.

Given the strength of the data - including a safety profile which Ionis Pharmaceuticals’ (Nasdaq: IONS) rival therapy inotersen has been unable to match - their confidence seems well placed.

Dr Akshay and Mr Greene say they will submit for approval in the USA and European Union this year, with a decision expected by the middle of 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK